Skip Navigation LinksHome > April 24, 2014 - Volume 28 - Issue 7 > Relationship of immunologic response to antiretroviral thera...
doi: 10.1097/QAD.0000000000000167
Clinical Science

Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence

Yanik, Elizabeth L.a; Napravnik, Soniaa; Cole, Stephen R.a; Achenbach, Chad J.b; Gopal, Satisha; Dittmer, Dirk P.a; Olshan, Andrew F.a; Kitahata, Mari M.c; Mugavero, Michael J.d; Saag, Michaeld; Moore, Richard D.e; Mathews, W. Christopherf; Hunt, Peterg; Eron, Joseph J.a

Collapse Box


Objective: To estimate the association between immunologic response to antiretroviral therapy (ART) and non-AIDS defining cancer (NADC) incidence in HIV-infected patients.

Design: A prospective cohort including patients with at least 1 cell/μl CD4+ cell count and HIV-1 RNA measure after ART initiation between 1996 and 2011 in the Centers for AIDS Research Network of Integrated Clinical Systems, a collaboration of eight HIV clinics at major academic medical centres in the United States.

Methods: Measures of immunologic response were 6-month CD4+ post-ART, latest CD4+ and CD4+ count-years, a cumulative measure of CD4+ lymphopenia. Cox regression with inverse probability-of-exposure weights was used to calculate adjusted hazard ratios of virus-related and virus-unrelated NADC incidence.

Results: Among 9389 patients at ART initiation, median CD4+ cell count was 200 cells/μl [interquartile range (IQR) 60–332)], and median HIV-1 RNA was 4.8 log10copies/ml (IQR 4.3–5.4). Median follow-up was 3.3 years (IQR 1.5–6.5). After 6 months of ART, median CD4+ cell count was 304 cells/μl (IQR 163–469). One hundred and sixty-four NADCs were diagnosed during study follow-up, 65 (40%) considered virus-related. Virus-related NADCs were inversely associated with 6-month CD4+ cell count (hazard ratio per 100 cells/μl increase = 0.71), latest CD4+ cell count (hazard ratio per 100 cells/μl increase = 0.70) and CD4+ cell count-years (hazard ratio per 200 cell-years/μl increase = 0.91) independent of CD4+ cell count at ART initiation, age and HIV-1 RNA response. No associations were found with virus-unrelated NADCs.

Conclusion: Poor CD4+ cell count response was strongly associated with virus-related NADC incidence, suggesting an important role for T-cell mediated immunity in pathogenesis. Lower CD4+ cell count proximal to cancer diagnosis may be a result of subclinical cancer. Intensified cancer screening should be considered for patients on ART with low CD4+ cell counts.

© 2014 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.